BMJ:未经治疗的TST或IGRA阳性人群后续结核病风险研究

2020-03-11 MedSci原创 MedSci原创

未经治疗的TST或IGRA阳性人群后续结核病发病风险较高

结核菌素皮肤试验(TST)或干扰素γ释放试验(IGRA)阳性患者被认为是结核病的高危人群。近日研究人员通过系统综述和荟萃研究考察上述测试阳性患者的结核病风险。

收集1990-2019年间相关资料,纳入本研究的临床试验至少包含10名未经治疗的患者,存在结核抗原呈阳性(包含在TST或IGRA中,或两者都有)并随访12个月。研究的主要终点为未经治疗的阳性人群每1000人-年结核病发病率。

研究包含122个临床研究。33?811名TST硬结≥10 mm的参与者的结核病发病率为0.3/1000人-年。在19个不同的高危人群研究中,116197个潜在结核病感染阳性患者的发病率始终高于一般人群。在所有类型的结核病接触者中,IGRA阳性者的结核发病率为17.0/1000人-年,而TST阳性结果≥5mm的参与者为8.4/ 1000人-年。在HIV感染者中, IGRA阳性结果的参与者结核病发病率为16.9%,TST阳性结果≥5mm的参与者为27.1。移民、矽肺患者或需要透析的患者、移植受者和囚犯的结核患病率较高。

研究认为,未经治疗的TST或IGRA阳性人群后续结核病发病风险较高。

原始出处:

Jonathon R Campbellet al. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis.BMJ. 10 March 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=963313, encodeId=db14963313dc, content=<a href='/topic/show?id=391de865327' target=_blank style='color:#2F92EE;'>#结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78653, encryptionId=391de865327, topicName=结核病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri May 07 09:18:49 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848975, encodeId=740718489e551, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 14 19:48:26 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055703, encodeId=bde62055e0324, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Aug 01 07:48:26 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952138, encodeId=dc131952138e8, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9529, encryptionId=a641952930, topicName=IGRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Sep 25 08:48:26 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254331, encodeId=e8fc125433105, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Mar 13 09:48:26 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605347, encodeId=f906160534e33, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Fri Mar 13 09:48:26 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=963313, encodeId=db14963313dc, content=<a href='/topic/show?id=391de865327' target=_blank style='color:#2F92EE;'>#结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78653, encryptionId=391de865327, topicName=结核病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri May 07 09:18:49 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848975, encodeId=740718489e551, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 14 19:48:26 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055703, encodeId=bde62055e0324, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Aug 01 07:48:26 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952138, encodeId=dc131952138e8, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9529, encryptionId=a641952930, topicName=IGRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Sep 25 08:48:26 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254331, encodeId=e8fc125433105, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Mar 13 09:48:26 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605347, encodeId=f906160534e33, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Fri Mar 13 09:48:26 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
    2021-02-14 gaoxiaoe
  3. [GetPortalCommentsPageByObjectIdResponse(id=963313, encodeId=db14963313dc, content=<a href='/topic/show?id=391de865327' target=_blank style='color:#2F92EE;'>#结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78653, encryptionId=391de865327, topicName=结核病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri May 07 09:18:49 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848975, encodeId=740718489e551, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 14 19:48:26 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055703, encodeId=bde62055e0324, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Aug 01 07:48:26 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952138, encodeId=dc131952138e8, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9529, encryptionId=a641952930, topicName=IGRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Sep 25 08:48:26 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254331, encodeId=e8fc125433105, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Mar 13 09:48:26 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605347, encodeId=f906160534e33, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Fri Mar 13 09:48:26 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=963313, encodeId=db14963313dc, content=<a href='/topic/show?id=391de865327' target=_blank style='color:#2F92EE;'>#结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78653, encryptionId=391de865327, topicName=结核病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri May 07 09:18:49 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848975, encodeId=740718489e551, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 14 19:48:26 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055703, encodeId=bde62055e0324, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Aug 01 07:48:26 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952138, encodeId=dc131952138e8, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9529, encryptionId=a641952930, topicName=IGRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Sep 25 08:48:26 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254331, encodeId=e8fc125433105, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Mar 13 09:48:26 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605347, encodeId=f906160534e33, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Fri Mar 13 09:48:26 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
    2020-09-25 sodoo
  5. [GetPortalCommentsPageByObjectIdResponse(id=963313, encodeId=db14963313dc, content=<a href='/topic/show?id=391de865327' target=_blank style='color:#2F92EE;'>#结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78653, encryptionId=391de865327, topicName=结核病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri May 07 09:18:49 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848975, encodeId=740718489e551, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 14 19:48:26 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055703, encodeId=bde62055e0324, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Aug 01 07:48:26 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952138, encodeId=dc131952138e8, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9529, encryptionId=a641952930, topicName=IGRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Sep 25 08:48:26 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254331, encodeId=e8fc125433105, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Mar 13 09:48:26 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605347, encodeId=f906160534e33, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Fri Mar 13 09:48:26 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=963313, encodeId=db14963313dc, content=<a href='/topic/show?id=391de865327' target=_blank style='color:#2F92EE;'>#结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78653, encryptionId=391de865327, topicName=结核病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri May 07 09:18:49 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848975, encodeId=740718489e551, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sun Feb 14 19:48:26 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055703, encodeId=bde62055e0324, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Aug 01 07:48:26 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952138, encodeId=dc131952138e8, content=<a href='/topic/show?id=a641952930' target=_blank style='color:#2F92EE;'>#IGRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9529, encryptionId=a641952930, topicName=IGRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Sep 25 08:48:26 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254331, encodeId=e8fc125433105, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Mar 13 09:48:26 CST 2020, time=2020-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605347, encodeId=f906160534e33, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Fri Mar 13 09:48:26 CST 2020, time=2020-03-13, status=1, ipAttribution=)]

相关资讯

遏制结核病,听听专家怎么说

世界卫生组织提出,到2035年,终止结核病流行,届时要将结核病患病率降到10/10万以下;国家卫生健康委刚刚发布的《遏制结核病行动计划(2019~2022年)》,则在《全国十三五结核病防治规划》基础上提出了具体任务。这些目标和计划的出台,为今后结防工作指出了新方向,我国结核病防治工作也迈入了新时代。日前,由中华医学会结核病学分会等主办的2019年全国结核病学术大会上,多位专家围绕上述主题作了分享。

Nature:结核菌致病有 “元凶”

近日,同济大学医学院、同济大学附属上海市肺科医院教授戈宝学团队联合上海科技大学饶子和院士团队研究发现,结核菌中有一种蛋白非常 “聪明”,它能利用人体的蛋白分子攻击自身免疫系统,从而导致结核病发生。相关成果 1 月 16 日在线发表于《自然》。

结核病耐药后无药可用?人工智能帮患者走出“至暗时刻”

在许多人印象中,结核病不过是一种过时的“白色瘟疫”。然而,“狡猾”的结核病并未被人类打败。

Lancet respir med:全血基因特征用于结核病的预测

研究发现,多数血液转录生物标志物仅能反应3-6个月的结核病风险,尚缺少满足WHO2年预测能力的生物标志物

Immunitor推出可在短短一个月内治疗结核病的突破性口服疫苗

Immunitor很高兴地公布其Tubivac(V7)的随机,安慰剂对照III期临床试验的阳性结果,该药物是口服治疗结核病(TB)的免疫佐剂,是一流的,可口服的治疗性疫苗。